Switzerland-based drugs company Debiopharm Group said it would support the country’s national pre-seed fund, Venture Kick, to help business ideas at Switzerland’s institutes of higher learning and universities.

Debiopharm is the first private company to join the ranks of the five foundations – Gebert Rüf Stiftung, Ernst Gohner Stiftung, OPO-Stiftung, Avina Stiftung and Fondation 1796 des Associés de la Maison de banquiers privés Lombard Odier Darier Hentsch & Cie – in Venture Kick, which has awarded SFr8.5m ($m) since 2007 to 233 spin-offs in a programme managed by IFJ Institut für Jungunternehmen.

The objective is to double the amount of spin-offs, by speeding up the process of launching a company and by making start-ups more attractive for professional investors. In order to meet its objectives, venture kick offers up to SFr130,000 in pre-seed capital.

Pascale Vonmont, president of Venture Kick’s strategy committee and Deputy Director of Gebert Rüf Stiftung, said…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?